← Back to Search

Peri-Articular Injections, Adductor Canal Block, and IPACK for Knee Arthritis (IPACK Trial)

Phase 4
Waitlist Available
Led By David H Kim, MD
Research Sponsored by Hospital for Special Surgery, New York
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with osteoarthritis scheduled for a primary either partial or total knee arthroplasty with a participating surgeon
Age 18 to 80 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours on post-operative day 1, 48 hours on post-operative day 2, and 72 hours on post-operative day 3
Awards & highlights

IPACK Trial Summary

A comparison of two pain control methods - the combination of Adductor Canal Block (ACB)/Periarticular Injection (PAI)/Infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (IPACK) versus the Periarticular Injection (PAI) - in patients undergoing total knee arthroplasty. Primary outcome is NRS pain scores with ambulation on postoperative day one (24 hours post-block administration).

Eligible Conditions
  • Knee Arthritis

IPACK Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check β€œYes” for the criteria below

IPACK Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours on post-operative day 1, 48 hours on post-operative day 2, and 72 hours on post-operative day 3
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours on post-operative day 1, 48 hours on post-operative day 2, and 72 hours on post-operative day 3 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Numeric Rating Scale (NRS) Pain Scores
Secondary outcome measures
Ambulation Distance During Physical Therapy
Hospital Length of Stay
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS Jr)
+5 more

IPACK Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Peri-Articular Injections, Adductor Canal Block, and IPACKExperimental Treatment7 Interventions
Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg) Injection prior to cementation bupivacaine 0.25% with epinephrine 30cc; methylprednisolone, 40 mg/ml, 1 ml cefazolin, 500 mg in 10 ml normal saline, 22cc Superficial injection prior to closure. a. 20cc 0.25% bupivacaine Adductor canal block technique (supine position, post IV sedation) a. Mid-thigh injection of 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone IPACK technique (supine position) a. 25 cc 0.25% bupivacaine
Group II: Peri-Articular Injections onlyActive Control7 Interventions
Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg) Injection prior to cementation bupivacaine 0.5% with epinephrine 30cc; methylprednisolone, 40 mg/ml, 1 ml cefazolin, 500 mg in 10 ml normal saline, 22cc Superficial injection prior to closure. 20cc 0.25% bupivacaine 2 mg IV dexamethasone.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine 20cc
2017
Completed Phase 4
~90
Bupivacaine with Dexamethasone
2017
Completed Phase 4
~90
Bupivacaine 25cc
2017
Completed Phase 4
~90
Bupivacaine with epinephrine
2017
Completed Phase 4
~110
Methylprednisolone
FDA approved
Cefazolin
FDA approved
8 MHz. Chiba needle
2017
Completed Phase 4
~90

Find a Location

Who is running the clinical trial?

Hospital for Special Surgery, New YorkLead Sponsor
242 Previous Clinical Trials
61,816 Total Patients Enrolled
David H Kim, MDPrincipal InvestigatorHospital for Special Surgery, New York
5 Previous Clinical Trials
723 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~11 spots leftby Mar 2025